Component-Resolved Diagnostics: Shedding Light on the So-Called ‘Squishy Science’ of Food Allergies?

Jennifer S. Kim  Anna Nowak-Węgrzyn

Division of Allergy and Immunology, Department of Pediatrics, Jaffe Food Allergy Institute, Mount Sinai School of Medicine, New York, N.Y., USA

Recently, the editors of the New York Times invited knowledgeable outside contributors to discuss the systematic review of the available evidence on the prevalence, diagnosis, management, and prevention of food allergies published in the Journal of the American Medical Association in 2010 [1]. They entitled their blog ‘The Squishy Science of Food Allergies’ [2], and it was a discussion triggered by the commissioned federal report which found that a uniform definition of what a food allergy is or how to test for one was lacking. There were few high-quality studies. The New York Times title may somewhat belittle the complexities of the diagnosis of food allergies but also conveys the difficulties inherent in our less-than-perfect testing modalities available for food allergy.

Modern society favors instant and definitive outcomes, primarily because technology has allowed for such. However, immediate conclusions cannot always be reasonably delivered in medicine and particularly in food allergy. Certainly, the diagnostic value of our current testing modalities via the blood and skin are limited by the relatively low positive predictive value (PPV) and are overly sensitive in detecting relevant specific IgE antibody. Component-resolved diagnostics (CRD) has been introduced recently as a promising tool to assess specific IgE antibodies against multiple recombinant or purified natural allergen components. CRD has been widely utilized for research purposes with the application of protein as well as peptide microarray chip technology. One of the advantages of the chip technology is the ability to obtain a wealth of information from a minute amount of blood, which is particularly helpful in infants and young children. CRD provides significant insights into the process of sensitization by defining the primary sensitizers, cross-reactivity patterns, and potential markers of systemic reactions in plant food allergy.

This issue’s article by Moverare et al. [3] evaluates 74 Swedish subjects with known peanut sensitization and a history of suspected peanut allergy. Within this cohort, 65% of subjects had specific IgE antibodies to Ara h 1, 2, or 3 whereas 35% had no detectable IgE antibodies to these recombinant peanut storage proteins. Among the group positive to Ara h 1–3, 60% of subjects had peanut-specific IgE levels >15 kU/l (median 21 kU/l) whereas all subjects in the group negative to Ara h 1–3 had peanut-
specific IgE levels <10 kU/l (median 0.73 kU/l); the difference was statistically significant. Based on questionnaire data, self-reported symptoms were also evaluated. Fifty-eight subjects (78%) reported a previous adverse reaction after peanut ingestion. However, no confirmatory oral challenges were performed. Respiratory distress (asthma or dyspnea) was not reported but a model was developed using Ara h 2, deemed the most important predictor of clinical allergy (and what that cutoff would be) using only Ara h for peanut-specific IgE (prick test meal wheal diameter ≥6 mm). While specific IgE to egg white (median 0.73 kU/l) was most useful in the diagnosis of allergy to raw egg white, ovo-mucoid-specific IgE (≥15 kU/l) was superior in predicting reactions to heated egg white.

Ott et al. [6] analyzed 145 oral challenges serving as reference parameters for CRD using microarray technology for suspected allergy to cow’s milk (n = 85) and hen’s eggs (n = 60). CRD was not shown to be capable of replacing oral food challenges, and testing with singular allergen components did not prove to be superior to in vitro testing for whole antigen (UniCAP; Phadia, Uppsala, Sweden). The authors suggest the use of microarrayed allergen components as a low-invasive tool because of the low amount of serum required for analysis; blood can be derived via capillaries instead of via peripheral venipuncture. However, diagnostic capability was not enhanced with use of CRD in this study.

Validation of CRD accuracy must occur with use of oral food challenges, the gold standard for diagnosing food allergy as affirmed by guidelines published in December 2010 by the NIAID-sponsored expert panel [7]. Similarly, the World Allergy Organization Clinical Guidelines on cow’s milk allergy (DRACMA) [8] did not find a diagnostic advantage for CRD in a GRADE methodology review of studies of cow’s milk allergen-specific IgE antibody measurement using microarrays [9, 10] and suggested that CRD should be used only in a research context [10]. However, CRD may help refine indications for oral challenges and encourage oral challenges in borderline situations such as when long-term avoidance has been instituted based on positive test results (>95% PPV) without a history of clinical reaction.

In conclusion, CRD may indeed prove to shed light on the ‘squishy science’ [2] of food allergy by providing more precise clinical immunologic data, but further evidence is necessary to define its applicability. It is unlikely that CRD will replace the current gold standard for food allergy diagnosis – an oral food challenge.

References


